Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Neuropharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1525498

TED (Trazodone Effectiveness in Depression): impact of trazodone extended release vs. SSRIs on the health status and quality of life of patients with major depressive disorder

Provisionally accepted
Marcin Siwek Marcin Siwek 1*Adrian Andrzej Chrobak Adrian Andrzej Chrobak 2Anna Julia Krupa Anna Julia Krupa 1Aleksandra Gorostowicz Aleksandra Gorostowicz 2Andrzej Juryk Andrzej Juryk 2Dominika Dudek Dominika Dudek 2
  • 1 Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University, Medical College, Krakow, Kraków, Poland
  • 2 Department of Adult Psychiatry, Chair of Psychiatry, Jagiellonian University, Medical College, Krakow, Kraków, Lesser Poland, Poland

The final, formatted version of the article will be published soon.

    Introduction: Early research of major depressive disorder (MDD) pharmacotherapy largely focused on symptomatic improvement, in recent years it's weight has shifted to functioning and quality of life. Generally, studies confirm that antidepressants improve the functional outcomes in MDD but very few have compared the efficacy of specific drugs. This work aimed to compare the impact of trazodone extended release (XR) vs. selective serotonin reuptake inhibitors (SSRIs) on health status and quality of life in MDD. Methods: The data of 180 subjects from a naturalistic observation Trazodone Effectiveness in Depression (TED) study were analyzed. Participants in TED received trazodone extended release (XR) or selective serotonin reuptake inhibitors (SSRIs) (flexible doses) for 12 weeks. Health status and health-related quality of life (HRQoL) were evaluated with EQ-5D-5L tool at baseline and weeks 2,4,8, and 12. Results: At baseline, subjects treated with trazodone XR vs. SSRIs presented similar health status profiles and levels of HRQoL in the dimensions of mobility, self-care and anxiety/depression, and lower scores in usual activities, pain/discomfort and overall HRQoL and health status. Both trazodone XR and SSRIs improved the health status and HRQoL of MDD patients on all consequent time-points. Trazodone XR in comparison to SSRIs provided larger improvements is self-care, usual activities, pain/discomfort, anxiety/depression domains and more often improved participants overall health status and HRQoL. More participants reported a mixed change in their health status and HRQoL in SSRIs than in trazodone XR group. Discussion: Health status and HRQoL improved in both treatment arms, with preferable scores in trazodone XR vs. SSRIs group.

    Keywords: Trazodone, Selective Serotonin Reuptake Inhibitors, Major Depressive Disorder, Quality of Life, EQ-5D-5L Angielski (Stany Zjednoczone) -sformatowano: Włoski (Włochy)

    Received: 09 Nov 2024; Accepted: 18 Dec 2024.

    Copyright: © 2024 Siwek, Chrobak, Krupa, Gorostowicz, Juryk and Dudek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Marcin Siwek, Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University, Medical College, Krakow, Kraków, Poland

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.